- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BOS 161721 | BOS161721
Compound class: Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 .
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|